(3a,6a-cis)-tetrahydrofuro[3,4-c]furan-1,3-dione | 149429-50-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 英文名称: (3a,6a-cis)-tetrahydrofuro[3,4-c]furan-1,3-dione
• 英文别名: tetrahydrofuro-[3,4-c]furan-1,3-dione；cis-tetrahydrofurano[3,4-c]furan-1,3-dione；1H,3H-Furo[3,4-c]furan-1,3-dione, tetrahydro-, cis-；(3aR,6aS)-1,3,3a,6a-tetrahydrofuro[3,4-c]furan-4,6-dione
• CAS: 149429-50-5
• 化学式: C₆H₆O₄
• 分子量: 142.111
• InChiKey: NEOVTTNLKPSNCL-ZXZARUISSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3a,6a-cis)-tetrahydrofuro[3,4-c]furan-1,3-dione 在 叠氮磷酸二苯酯 、 sodium methylate 、 三乙胺 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 29.0h， 生成 methyl 4-(tert-butoxycarbonylamino)tetrahydrofuran-3-carboxylate
  参考文献：
  名称：

  [EN] BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  [FR] COMPOSÉS PONTÉS POUR LE TRAITEMENT DES INFECTIONS BACTÉRIENNES

  摘要：

  本文披露了新型的桥接化合物，以及它们的药用盐、水合物和前药。还披露了包含这些化合物的组合物，制备这些化合物的方法以及将这些化合物用作抗菌剂的方法。所披露的化合物、其药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，对治疗细菌感染及相关疾病和症状是有用的。

  公开号：

  WO2016123146A1
• 作为产物：
  描述：

  dimethyl tetrahydrofuran-3,4-dicarboxylate 在 盐酸 、 乙酸酐 作用下， 以 水 为溶剂， 反应 62.0h， 生成 (3a,6a-cis)-tetrahydrofuro[3,4-c]furan-1,3-dione
  参考文献：
  名称：

  [EN] BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  [FR] COMPOSÉS PONTÉS POUR LE TRAITEMENT DES INFECTIONS BACTÉRIENNES

  摘要：

  本文披露了新型的桥接化合物，以及它们的药用盐、水合物和前药。还披露了包含这些化合物的组合物，制备这些化合物的方法以及将这些化合物用作抗菌剂的方法。所披露的化合物、其药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，对治疗细菌感染及相关疾病和症状是有用的。

  公开号：

  WO2016123146A1

文献信息

• [EN] NOVEL HEPATITIS C VIRUS INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：MEDIVIR AB

  公开号：WO2013095275A1

  公开（公告）日：2013-06-27

  The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

  本发明提供了式(I)的化合物：其中环A和A'独立地是5个成员的可选取代的芳香杂环；Q是C(=O)NR1R1'或式U是C(R4)2，O，S，S(=O)2，C(R4)2C(R4)2，CH2O，OCH2，CH2S，SCH2，CH2S(=O)2，S(=O)CH2或C=C(Ru)2；X是CH2，CHR12，CR12R12，O，S，S(=O)2或NRx；m是0，1，2或3；n是0，1，2或3；其他变量如权利要求中所定义，用于治疗或预防丙型肝炎病毒感染，以及相关方面。
• Compounds for the treatment of bacterial infections
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3050888A1

  公开（公告）日：2016-08-03

  Novel bridged compounds of formula (I) are disclosed herein, along with their pharmaceutically acceptable salts and hydrates. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

  本文公开了式 (I) 的新型桥联化合物及其药学上可接受的盐类和水合物。还公开了包含此类化合物的组合物、制备此类化合物的方法以及将此类化合物用作抗菌剂的方法。所公开的化合物、它们的药学上可接受的盐、水合物和原药，以及包含这些化合物、盐、水合物和原药的组合物，可用于治疗细菌感染及相关疾病和病症。
• Synthesis and biological activity of Δ-5,6-norcantharimides: importance of the 5,6-bridge
  作者：Ali Thaqi、Janet L. Scott、Jayne Gilbert、Jennette A. Sakoff、Adam McCluskey

  DOI：10.1016/j.ejmech.2010.01.004

  日期：2010.5

  Cantharidin (1) and norcantharidin (2) are potent protein phosphatase 1 and 2A inhibitors that also display high levels of anticancer activity against a broad range of tumor cells lines. Surprisingly, Delta-5,6-ethyl norcantharidin (3, cis-tetrahydrofurano[3,4-c]furan-1,3-dione) displays neither phosphatase inhibition nor anticancer activity. This suggests that the 5,6-ethyl bridge is pivotal to both anti-cancer and protein phosphatase activity. Additionally bioisosteric replacement of the ethereal oxygen has no effect on biological activity nor does modification of the anhydride moiety. Unlike the parent norcantharidin. anhydride ring opening has no effect on either protein phosphatase inhibition or anti-cancer activity. Additionally, this work highlights the discovery of the octyl substituted, cis-5-benzyl-2-hexyltetrahydro-2H,3aH-pyrrolo[3,4-c]pyrrole-1,3-dione, 9p, and the octyl substituted, cis-octyltetrahydro-5H-furo[3,4-c]pyrrole-4,6-dione, 8p, as two new cytotoxic agents which are equipotent (9p) with, and more potent (8p) than norcantharidin. Crown Copyright (C) 2010 Published by Elsevier Masson SAS. All rights reserved.
• US5276169A
  申请人：——

  公开号：US5276169A

  公开（公告）日：1994-01-04
• [EN] BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS PONTÉS POUR LE TRAITEMENT DES INFECTIONS BACTÉRIENNES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016123146A1

  公开（公告）日：2016-08-04

  Novel bridged compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

  本文披露了新型的桥接化合物，以及它们的药用盐、水合物和前药。还披露了包含这些化合物的组合物，制备这些化合物的方法以及将这些化合物用作抗菌剂的方法。所披露的化合物、其药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，对治疗细菌感染及相关疾病和症状是有用的。